Free Trial

GlucoTrack Q4 2023 Earnings Report

GlucoTrack logo
$0.20 -0.03 (-11.75%)
As of 03/28/2025 04:00 PM Eastern

GlucoTrack EPS Results

Actual EPS
-$10.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GlucoTrack Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GlucoTrack Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

GlucoTrack Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Glucotrack finalizes equity securities sales
Glucotrack appoints Umpierrez to Medical Advisory Board
See More GlucoTrack Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GlucoTrack? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GlucoTrack and other key companies, straight to your email.

About GlucoTrack

GlucoTrack (NASDAQ:GCTK), a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

View GlucoTrack Profile

More Earnings Resources from MarketBeat